Valneva (NASDAQ:VALN) Price Target Cut to $23.00

Valneva (NASDAQ:VALN) had its price objective decreased by HC Wainwright from $26.00 to $23.00 in a report published on Wednesday, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Valneva’s Q3 2024 earnings at ($0.29) EPS, Q4 2024 earnings at ($0.20) EPS, FY2025 earnings at ($1.14) EPS and FY2026 earnings at ($0.38) EPS.

Valneva Stock Up 1.6 %

NASDAQ VALN opened at $6.21 on Wednesday. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.15 and a current ratio of 2.63. Valneva has a 52 week low of $5.70 and a 52 week high of $14.49. The stock has a market capitalization of $432.46 million, a P/E ratio of -15.15 and a beta of 2.19. The stock has a fifty day moving average of $7.06 and a 200-day moving average of $7.57.

Valneva (NASDAQ:VALN) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.02. The firm had revenue of $40.97 million during the quarter, compared to analysts’ expectations of $46.83 million. Valneva had a negative return on equity of 20.01% and a negative net margin of 21.31%. On average, equities research analysts forecast that Valneva will post 0.02 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Valneva stock. AlphaCentric Advisors LLC grew its stake in shares of Valneva SE (NASDAQ:VALN) by 42.3% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 88,252 shares of the company’s stock after buying an additional 26,248 shares during the period. AlphaCentric Advisors LLC owned approximately 0.13% of Valneva worth $649,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.